Skip to main content
. 2016 Apr 29;90(10):5031–5046. doi: 10.1128/JVI.03211-15

TABLE 4.

Neutralization of BNM-III-170-treated HIV-1JR-FL by monoclonal antibodies from vaccinated monkeys and humansa

Monoclonal antibody gp120 epitope IC50 (μg/ml) for:
HIV-1JR-FL
A-MLV
Without BNM-III-170 With BNM-III-170 Without BNM-III-170 With BNM-III-170
17b CD4i >30 0.6 ± 0.4 >30 >30
902090 V2 (171–177) >30 5.0 ± 2.4 >30 >30
830A Fab Discontinuous V2i epitope >10 0.6 >10 >10
900973 C terminus (491–501) >30 >30 >30 >30
900974 V3 (304–317) >30 0.2 ± 0.0 >30 >30
900990 V3 (318–327) >30 5.1 >30 >30
902067 V3 (304–314) >30 0.2 ± 0.0 >30 >30
GE2 JG8 V3 (301–317) >100 0.6 >100 >100
CH22 V3 (304–320) >30 0.2 >30 >30
CH23 V3 (302–318) >30 3.3 >30 22.1
a

The antibody concentration (IC50) that inhibited the infection of the recombinant viruses by 50% in the absence or presence of 30 μM BNM-III-170 is reported. In this assay, the IC50s of BNM-III-170 alone were 20.7 ± 7.6 μM for HIV-1JR-FL and >100 μM for A-MLV.